DE602005022083D1 - Methansulfonatsalze von abirateron-3-estern und wiederherstellung von salzen von abirateron-3-estern durch auflösung in methyl-tert-butyl-ether - Google Patents

Methansulfonatsalze von abirateron-3-estern und wiederherstellung von salzen von abirateron-3-estern durch auflösung in methyl-tert-butyl-ether

Info

Publication number
DE602005022083D1
DE602005022083D1 DE602005022083T DE602005022083T DE602005022083D1 DE 602005022083 D1 DE602005022083 D1 DE 602005022083D1 DE 602005022083 T DE602005022083 T DE 602005022083T DE 602005022083 T DE602005022083 T DE 602005022083T DE 602005022083 D1 DE602005022083 D1 DE 602005022083D1
Authority
DE
Germany
Prior art keywords
esters
salts
tert
butyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005022083T
Other languages
English (en)
Inventor
Neil John Hunt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Publication of DE602005022083D1 publication Critical patent/DE602005022083D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602005022083T 2004-08-24 2005-08-23 Methansulfonatsalze von abirateron-3-estern und wiederherstellung von salzen von abirateron-3-estern durch auflösung in methyl-tert-butyl-ether Active DE602005022083D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60355904P 2004-08-24 2004-08-24
GBGB0418900.7A GB0418900D0 (en) 2004-08-24 2004-08-24 Novel salt forms
PCT/GB2005/003282 WO2006021776A1 (en) 2004-08-24 2005-08-23 Methanesulfonate salts of abiraterone-3-esters and recovery of salts of abirater one-3-esters from solution in methyl tert-butyl ether

Publications (1)

Publication Number Publication Date
DE602005022083D1 true DE602005022083D1 (de) 2010-08-12

Family

ID=33104570

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005022083T Active DE602005022083D1 (de) 2004-08-24 2005-08-23 Methansulfonatsalze von abirateron-3-estern und wiederherstellung von salzen von abirateron-3-estern durch auflösung in methyl-tert-butyl-ether

Country Status (22)

Country Link
US (5) US7700766B2 (de)
EP (1) EP1789432B1 (de)
JP (1) JP5069561B2 (de)
KR (2) KR101245727B1 (de)
CN (2) CN101044155B (de)
AT (1) ATE472553T1 (de)
AU (1) AU2005276298C1 (de)
BR (1) BRPI0514543A (de)
CA (1) CA2576922C (de)
CY (1) CY1110800T1 (de)
DE (1) DE602005022083D1 (de)
DK (1) DK1789432T3 (de)
ES (1) ES2345345T3 (de)
GB (1) GB0418900D0 (de)
HK (2) HK1103091A1 (de)
MX (1) MX2007002032A (de)
NZ (1) NZ553085A (de)
PL (1) PL1789432T3 (de)
PT (1) PT1789432E (de)
SI (1) SI1789432T1 (de)
WO (1) WO2006021776A1 (de)
ZA (1) ZA200701533B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
DK1781683T3 (da) * 2004-08-24 2012-02-06 Btg Int Ltd Fremgangsmåde til fremstilling af 17-vinyl-triflater som halvfabrikata
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
HUE054495T2 (hu) * 2006-08-25 2021-09-28 Janssen Oncology Inc Rák kezelésére szolgáló készítmény
KR101360725B1 (ko) 2009-06-26 2014-02-07 노파르티스 아게 Ｃｙｐ17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102030798B (zh) * 2010-12-17 2012-10-17 深圳万乐药业有限公司 一种醋酸阿比特龙的纯化方法
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
WO2013053691A1 (en) * 2011-10-10 2013-04-18 Zach System Process for preparing 17-substituted steroids
EP2607371A1 (de) 2011-12-23 2013-06-26 Crystal Pharma, S.A.U. Verfahren zur Herstellung von Abirateron und verwandten Verbindungen
CN103172690B (zh) * 2011-12-23 2016-08-24 重庆医药工业研究院有限责任公司 醋酸阿比特龙及其中间体的制备方法
CN105461777B (zh) * 2012-01-04 2017-07-18 连云港润众制药有限公司 一种醋酸阿比特龙的纯化方法
CN103254265B (zh) * 2012-02-21 2016-07-13 上海希迈医药科技有限公司 醋酸阿比特龙三氟乙酸盐及其制备方法和应用
CN103360458B (zh) * 2012-03-26 2015-05-20 信泰制药（苏州）有限公司 一种阿比特龙的合成方法
CN102731605B (zh) * 2012-06-19 2016-04-13 鲁南制药集团股份有限公司 一种醋酸阿比特龙的纯化方法
CN103665084A (zh) * 2012-09-04 2014-03-26 重庆安格龙翔医药科技有限公司 一种制备醋酸阿比特龙的方法
CN102816200B (zh) * 2012-09-05 2015-04-15 中山大学 一种醋酸阿比特龙的制备方法
CN102816201A (zh) * 2012-09-25 2012-12-12 成都伊诺达博医药科技有限公司 一种阿比特龙的纯化方法
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
ITMI20121788A1 (it) 2012-10-22 2014-04-23 Olon Spa Procedimento per la purificazione di abiraterone acetato
CA2890589A1 (en) 2012-11-09 2014-05-15 Synthon Bv Process for making abiraterone-3-acetate
EP2917226A1 (de) 2012-11-09 2015-09-16 Synthon BV Verfahren zur herstellung des 17-triflat-zwischenprodukts von abirateron-3-acetat
TWI570131B (zh) * 2012-11-13 2017-02-11 賽克系統公司 製備１７－經取代類固醇之方法
WO2014075978A1 (en) 2012-11-16 2014-05-22 Synthon B.V. Process for the production of abiraterone-3-acetate involving an enol trliflation reaction in the presence of an alkoxy-pyridine compound
CN103059091B (zh) * 2012-11-22 2017-04-19 常州靶点医药科技有限公司 一种避免重金属残留的醋酸阿比特龙的制备方法
US9962452B2 (en) 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
PL2792682T3 (pl) 2013-04-19 2017-04-28 Zach System Sposób wytwarzania stałej postaci octanu abirateronu
CN103242410B (zh) * 2013-05-09 2015-08-26 苏州明锐医药科技有限公司 醋酸阿比特龙的制备方法
IN2013MU02133A (de) * 2013-06-24 2015-06-05 Sun Pharmaceutical Ind Ltd
KR20160024930A (ko) * 2013-06-28 2016-03-07 시노팜 타이완 리미티드 아비라테론 및 이의 중간체의 제조를 위한 방법
CZ306623B6 (cs) 2013-07-04 2017-04-05 Zentiva, K.S. Soli abirateronu acetátu
EP3080141A1 (de) 2013-12-12 2016-10-19 Basf Se Feste form von abirateronacetat
EP3099701B1 (de) 2014-01-28 2019-07-24 OLON S.p.A. Verfahren zur herstellung von abirateronacetat und zwischenprodukte davon
CN103965282B (zh) 2014-04-21 2016-01-20 武汉百科药物开发有限公司 一种醋酸阿比特龙的制备方法
US9315541B2 (en) * 2014-05-20 2016-04-19 Olon S.P.A. Process for the preparation of unsaturated trifluoromethanesulfonate steroid derivatives
CN105294806A (zh) * 2014-06-13 2016-02-03 江苏希迪制药有限公司 一种制备醋酸阿比特龙中间体的方法
US9937259B2 (en) 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
WO2016065139A1 (en) 2014-10-24 2016-04-28 Fl Therapeutics Llc 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
CN104447934B (zh) * 2014-12-08 2017-03-15 深圳科兴生物工程有限公司 一种醋酸阿比特龙的纯化方法
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
WO2018071544A1 (en) 2016-10-11 2018-04-19 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivative and formulations thereof
CN108586561B (zh) * 2018-04-03 2020-08-04 科兴生物制药股份有限公司 一种制备醋酸阿比特龙的方法
AU2020232706A1 (en) * 2019-03-06 2021-09-16 Propella Therapeutics, Inc. Abiraterone prodrugs
CN112812147A (zh) * 2019-11-15 2021-05-18 江苏佳尔科药业集团股份有限公司 一种醋酸阿比特龙的合成方法及其中间体
WO2022174134A1 (en) 2021-02-15 2022-08-18 Propella Therapeutics, Inc. Abiraterone prodrugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
DE69327096T2 (de) 1992-03-31 2000-06-21 Btg Int Ltd 17-substituierte steroide, verwendbar bei behandlung von krebs
ATE176481T1 (de) 1993-09-30 1999-02-15 Btg Int Ltd Synthese von 17-(3-pyridyl) steroiden
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms

Also Published As

Publication number Publication date
MX2007002032A (es) 2007-10-11
CA2576922C (en) 2013-05-07
US20070249836A1 (en) 2007-10-25
US20100152437A1 (en) 2010-06-17
US7700766B2 (en) 2010-04-20
CN101044155B (zh) 2012-10-10
GB0418900D0 (en) 2004-09-29
CA2576922A1 (en) 2006-03-02
US8076474B2 (en) 2011-12-13
HK1103091A1 (en) 2007-12-14
WO2006021776A1 (en) 2006-03-02
US20150329585A1 (en) 2015-11-19
DK1789432T3 (da) 2010-08-16
PL1789432T3 (pl) 2010-11-30
AU2005276298A1 (en) 2006-03-02
US8338588B2 (en) 2012-12-25
NZ553085A (en) 2010-08-27
CY1110800T1 (el) 2015-06-10
EP1789432B1 (de) 2010-06-30
KR101245727B1 (ko) 2013-03-25
KR20120135931A (ko) 2012-12-17
JP2008510780A (ja) 2008-04-10
JP5069561B2 (ja) 2012-11-07
SI1789432T1 (sl) 2010-10-29
US20130090468A1 (en) 2013-04-11
ZA200701533B (en) 2008-08-27
KR101358661B1 (ko) 2014-02-07
CN102863498A (zh) 2013-01-09
AU2005276298C1 (en) 2012-02-02
EP1789432A1 (de) 2007-05-30
CN102863498B (zh) 2015-04-08
ATE472553T1 (de) 2010-07-15
KR20070049171A (ko) 2007-05-10
US20120053340A1 (en) 2012-03-01
HK1180694A1 (en) 2013-10-25
AU2005276298B2 (en) 2011-06-23
BRPI0514543A (pt) 2008-06-17
ES2345345T3 (es) 2010-09-21
PT1789432E (pt) 2010-08-09
CN101044155A (zh) 2007-09-26

Similar Documents

Publication Publication Date Title
DE602005022083D1 (de) Methansulfonatsalze von abirateron-3-estern und wiederherstellung von salzen von abirateron-3-estern durch auflösung in methyl-tert-butyl-ether
ATE509935T1 (de) Mischungen aus mono-carboxylfunktionalisierten dialkylphosphinsäuren, ein verfahren zu ihrer herstellung und ihre verwendung
ES2564807T3 (es) Proceso para preparación de rosuvastatina de calcio amorfa pura
RS52214B (en) HDAC INHIBITOR PHARMACEUTICAL FORMULATIONS
BRPI0621386B8 (pt) composição farmacêutica para o uso externo
DK2020996T3 (da) Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme
BR0307408A (pt) Tripeptìdeos tendo um éter de hidroxipolina de uma quinolina substituìda para a inibição de ns3 (hepatite c)
EA200500239A1 (ru) Новый способ синтеза (1s)-4-,5-диметокси-1-(метиламинометил)-бензоциклобутана и его солей присоединения и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
NO20072930L (no) Tripentylcitrater og deres anvendelse
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
AR061134A1 (es) Derivados de tioxantina
RS51725B (en) N-METHYLAMINOMETHYL ISOINDOL COMPOUNDS AND COMPOSITIONS CONTAINING THEM AND USING THE SAME
CU20080213A7 (es) Nuevo procedimiento para la preparación de un intermediario útil en la preparación de imidazotriazinonas sustituidas con sulfonamida
ES2531190T3 (es) Método para producir un compuesto de 4-oxoquinolina
UY28897A1 (es) Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb
HRP20080027T3 (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
EA200901563A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
PA8638201A1 (es) Forma cristalina alfa del ranelato de estroncio procedimiento para su preparacion y composiciones farmaceuticas que la contienen
EA200900707A1 (ru) Новый способ синтеза 7,8-диметокси-1,3-дигидро-2h-3-бензазепин-2-она, и его применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
UY30300A1 (es) Compuestos triarílicos y sus derivados
AR060568A1 (es) Acidos bifenilcarboxilicos substituidos y sus derivados
EA200800324A1 (ru) Новый способ получения солей тиотропия
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
AR073871A1 (es) Intermediario de fulvestran
TW200718673A (en) Process for producing aromatic sulfonic acid compound